AllTranz, Inc. is a specialty pharmaceutical company based in Lexington, KY and founded in 2004. AllTranz will be a leader in the development of innovative pharmaceutical products delivered via unique dermal solutions to treat a variety of neuroscience disorders. AllTranz leverages proprietary technology to modify existing chemical entities with proven clinical outcomes to produce important new pharmaceutical products that extend patent franchises. The Company’s expertise in formulation, prodrug development, and dermal delivery products exploits the opportunity for lower risk development pathways to significant new drugs. These new products can improve drug dosing, patient compliance and/or reduce side effects. The AllTranz lead product is a proprietary synthetic cannabinoid for moderate to severe pain delivered via gel. The initial indication for the lead product is for the treatment of osteoarthritis.
News Headline
AllTranz Awarded $4 Million Research Grant by NIH and NIDA.
AllTranz has begun raising Series B round funds
Patent No. 7,511,054 has been issued to AllTranz by the U.S. Patent and Trademark Office